- ≥99% (HPLC)
- White to off-white solid
- DMSO or DMF (both 20 mg/ml), ethanol (1mg/ml) or water (<1mg/ml)
Category: API's & Intermediates
MK-4827 is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC50s=3.8 and 2.1nM, respectively). It inhibits the proliferation of cancer cells carrying the breast cancer mutations BRCA1 and BRCA2 in vitro and has efficacy alone against a xenograft of BRCA1-deficient cancer in mice. MK-4827 sensitizes human lung and breast cancer xenografts to radiation in mice.3 Formulations containing MK-4827 are effective against ovarian cancer.
Niraparib tosylate, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 4 methylbenzenesulfonate
White to off-white solid
DMSO or DMF (both 20 mg/ml), ethanol (1mg/ml) or water (<1mg/ml)
|Short Term Storage||
|Long Term Storage||
Protect from light and moisture.
|Use / Stability||
Stable for at least 2 years after receipt when stored at -20°C.
Not dangerous goods
(1) P. Jones, et al., J. Med. Chem. 52, 7170 (2009), (2) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011), (3) L. Wang, et al., Invest. New Drugs 30, 2113 (2012), (4) M.R. Mirza, et al., N. Engl. J. Med. 375, 2154 (2016), (5) K.N. Moore, et al., Gynecol. Oncol. 149, 214 (2018) (Review)
10 mg, 50 mg, Bulk